SGLT2 inhibitor trials in heart failure

SGLT2 inhibitors are under investigation in patients with heart failure with reduced and preserved ejection fraction, in and out of the hospital. This module summarises the trials in these populations.

SGLT2 inhibitor trials in heart failure
Rate this content
  • SGLT2 inhibitor trials in heart failure
  • SGLT2 inhibitor trials in heart failure
  • SGLT2 inhibitors have been shown to reduce the risk of CV events, including HHF, in patients with T2D regardless of HF
  • Several outcomes trials have been designed to investigate the effects of SGLT2 inhibitors in patients with HF, with and without T2D
  • Trials are also investigating the impact of SGLT2 inhibitor use on functional capacity, mechanisms and effects in the hospital setting
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go